Bob Daber, President & CTO
Today, the Pharma industry spends considerable time and expense in genomics, discovering and developing new drugs as well as developing companion diagnostics to identify those patients who might benefit the most. By the same token, they often lack the bioinformatics expertise or user-friendly solutions needed to analyze the massive amount of genomic data required. Additionally, in the United States, there are no large-scale biobanks of consented patients with specific genotype-phenotype signature. This leads to a lack of meaningful data for drug discovery and development. That’s where a complete genomics solution proves to be essential to drug development as it can enable everything from detailed analysis, quality control, extracting maximal information to reconciling clinical and patient characteristics. As genomics’ role becomes increasingly crucial in the drug development process and patient treatment decisions, the need for enterprise software that can be utilized from research and development to clinical and commercial applications becomes even more apparent and imperative. With its outstanding automated sequencing laboratory and proprietary technology, Genosity has built Integrated Genomic Toolkit (IGT) from scratch. IGT is a genomic software platform that is not only utilized in its own laboratory but also made available commercially to other labs. It is thus uniquely positioned to fulfill the needs across the whole spectrum.
IGT is built for genomic laboratories and is based on the company’s decades of combined experience running high-throughput clinical next-generation sequencing laboratories in a highly regulated environment. Genosity provides extensive lab and bioinformatic services to pharma companies that do not have deep expertise in genomics or regulatory requirements around genomic testing. “We have validated a variety of bioinformatic pipelines in our own laboratory to help process the data to detect different types of genomic alterations across variety of tests,” says Bob Daber, the CTO of Genosity.
We have validated a variety of bioinformatics pipelines in our own laboratory to help process the data to detect different types of genomic alterations across variety of tests
Additionally, as Genosity’s software customer base increases with more hospital health systems, Genosity can play an honest broker between health systems and pharma companies to provide access to testing and clinical trials.
Daber mentions that genomics is hard, and clinical genomics is harder since it has to deal with a staggering amount of data in a regulated environment. While genomics is used for cancer, rare disorders, women’s health issues, pharmacogenomics, etc., the process is the same. Genosity software solution is an end to end solution from patient sample to sequencer to analysis to report to the physician with a knowledge base to provide further analysis. It is integrated yet modular.
Informatics and Technical expertise are the basis of Genosity’s value proposition. In an instance, an IVD company working with an academic research group wanted to develop an assay that looks to monitor cancer fragments and circulating DNA in the blood that is reflective of the patients’ particular tumor. Using Technical Expertise and Software, Genosity did the lab work for the research. Using the IGT software, Genosity works with Pharma partners in clinical trials and licenses the software for potential distribution to the IVD Company.
Evidently, the scope of expertise and experience of Genosity is unmatched. The company’s Integrated Genosity Toolkit (IGT) is unlike anything on the market anywhere. What makes the company different is that not only do they not have a true competitor for IGT, but there isn’t a commercial software provider similar to them that has its own laboratory (yet). “Looking ahead, we want to enable drug development and technical expertise and informatics are key. We launched our software in Fall 2019. We plan to expand our commercialization efforts towards end of this year once health systems are past COVID-19 related issues. On our lab side, we plan to further expand our lab and informatics services in Oncology,” concludes Daber.